Could a drug combo replace radiation for rectal cancer?
NCT ID NCT07127497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of chemotherapy and an immunotherapy drug (sintilimab) can effectively treat locally advanced rectal cancer without the need for radiation. The goal is to shrink or eliminate tumors before surgery, potentially preserving organ function. The trial involves 50 adults with a specific type of rectal cancer who cannot tolerate or wish to avoid radiotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT CHEMOIMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Rearranging the treatment timeline: could a new sequence of chemo and radiation spare rectal cancer patients from major surgery?
- Rectal cancer: could a 'Watch and Wait' strategy spare patients from major surgery?
- Dye-Free laser imaging could replace standard dye in colorectal surgery
- Could your own gut bacteria restore bowel control after cancer surgery?
- New drug combo aims to eliminate rectal tumors before surgery
- Giving cancer patients a say in genetic results may boost knowledge and satisfaction